[-] Show simple item record

dc.contributor.authorCollier, Roberteng
dc.coverage.spatialUnited Stateseng
dc.date.issued2000eng
dc.description.abstractIn the United States (US) and European Union (EU) the regulatory and commercialization process for recombinant bovine somatotropin (rbST) had widely differing outcomes. Although the regulatory process in both locations was completed in 1993 the commercialization of rbST in the US has been highly successful while completely failing in the EU. This paper examines these events from the US perspective and concludes that reasons for the difference in commercial success lie in the cultural, regulatory, and political background differences between the two world locations.eng
dc.description.bibrefIncludes bibliographical referenceseng
dc.identifier.citationAgBioForum 3(2&3) 2000: 156-163.eng
dc.identifier.issn1522-936Xeng
dc.identifier.urihttp://hdl.handle.net/10355/1158
dc.languageEnglisheng
dc.publisherAgBioForumeng
dc.relation.ispartofcollectionAgBioForum, vol. 3, no. 2&3 (2000)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
dc.source.urihttp://www.agbioforum.missouri.edu/v3n23/v3n23a14-collier.htmeng
dc.subjectsomatotropineng
dc.subjectdairy cattleeng
dc.subjectregulatory processeng
dc.subject.lcshRecombinant bovine somatotropin -- Government policyeng
dc.titleRegulation of rbST in the USeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record